Belite Bio (STU:D01) Altman Z2-Score: 57.44 (As of Jul. 17, 2026) — 117% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:D01 Belite Bio Inc STU:D01
20 GF Score
Price €131.00
! 3 Warning Signs
View Full Analysis

What is Belite Bio Altman Z2-Score?

Belite Bio STU:D01 +1.55% 20 Altman Z2-Score is 57.44 as of Jul. 17, 2026, which is 117% above its 10-year median of 26.44. GuruFocus rates STU:D01 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,391 Biotechnology companies, Belite Bio ranks better than 98.99% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Belite Bio has a Altman Z2-Score of 57.44, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Belite Bio's Altman Z2-Score or its related term are showing as below:

STU:D01' s Altman Z2-Score Range Over the Past 10 Years
Min: -3.2   Med: 26.44   Max: 82.97
Current: 57.44

During the past 6 years, Belite Bio's highest Altman Z2-Score was 82.97. The lowest was -3.20. And the median was 26.44.


Belite Bio  (STU:D01) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Belite Bio Altman Z2-Score Related Terms


Belite Bio Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Belite Bio's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Altman Z2-Score Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial -3.20 16.90 23.82 26.44 82.97

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.69 28.34 37.55 82.97 57.44

STU:D01 vs DFTX, LGND, XENE: Altman Z2-Score Comparison

For the Biotechnology subindustry, Belite Bio's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Belite Bio Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Belite Bio's Altman Z2-Score falls into.


STU:D01
20GF Score
Belite Bio Inc STU:D01
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Belite Bio's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.6433+3.26*0+6.72*-0.1105+1.05*51.3968
=57.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was €701.75 Mil.
Total Current Assets was €451.41 Mil.
Total Current Liabilities was €0.00 Mil.
Retained Earnings was €0.00 Mil.
Pre-Tax Income was -23.301 + -21.627 + -18.48 + -14.149 = €-77.56 Mil.
Interest Expense was 0 + -0.0020000000000002 + 0 + 0 = €-0.00 Mil.
Total Liabilities was €13.39 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(451.412 - 0)/701.749
=0.6433

X2=Retained Earnings/Total Assets
=0/701.749
=0

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-77.557 - -0.0020000000000002)/701.749
=-0.1105

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(688.357 - 0)/13.393
=51.3968

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Belite Bio has a Altman Z2-Score of 57.44 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 57.44 mean?
Belite Bio (STU:D01) has a Altman Z2-Score of 57.44 as of Jul. 17, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Belite Bio and its competitors. This is 117% above median its historical median of 26.44. According to the industry distribution chart, Belite Bio ranks #14 out of 1391 companies in the Biotechnology industry, placing it in the top 1%.
Is Belite Bio's Altman Z2-Score too high?
Belite Bio's current Altman Z2-Score of 57.44 is 117% above median its 10-year median of 26.44. Based on the distribution chart, Belite Bio ranks #14 out of 1391 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Belite Bio has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Altman Z2-Score compare to DFTX and LGND?
According to the Biotechnology industry distribution chart, Belite Bio ranks #14 out of 1391 companies for Altman Z2-Score. This places Belite Bio in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Belite Bio and its competitors. Belite Bio's current Altman Z2-Score is 57.44, which is 117% above median its own 10-year median of 26.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (STU:D01) has a current Altman Z2-Score of 57.44. The current Altman Z2-Score is 57.44, which is 117% above median its 10-year median of 26.44. Belite Bio's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Belite Bio (STU:D01), the current Altman Z2-Score is 57.44 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belite Bio Business Description

Other Exchanges BLTE:USA
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
20GF Score

Get the complete analysis for STU:D01

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€131.00
Price